News >

FDA Grants Atezolizumab Regimen Priority Review for Frontline SCLC

Jason M. Broderick and Kristie L. Kahl
Published: Wednesday, Dec 05, 2018

Dr. Sandra Horning

Sandra Horning, MD
The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for atezolizumab (Tecentriq) for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Atezolizumab has approved FDA indications for non–small cell lung cancer and urothelial carcinoma.

References

  1. Liu S, Mansfield A, Szczesna S, et al. IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. Presented at: the IASLC 19th World Conference on Lung Cancer; September 23-26; Toronto, Canada. Abstract PL02.07.
  2. Liu S, Mansfield A, Szczesna S, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. NEJM. 2018;doi:10.1056/NEJMoa1809064.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Publication Bottom Border
Border Publication
x